FIC20230016I1 - Nirsevimabi - Google Patents

Nirsevimabi

Info

Publication number
FIC20230016I1
FIC20230016I1 FIC20230016C FIC20230016C FIC20230016I1 FI C20230016 I1 FIC20230016 I1 FI C20230016I1 FI C20230016 C FIC20230016 C FI C20230016C FI C20230016 C FIC20230016 C FI C20230016C FI C20230016 I1 FIC20230016 I1 FI C20230016I1
Authority
FI
Finland
Prior art keywords
nirsevimab
Prior art date
Application number
FIC20230016C
Other languages
English (en)
Finnish (fi)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of FIC20230016I1 publication Critical patent/FIC20230016I1/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10RNA viruses
    • C07K16/11Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FIC20230016C 2014-01-15 2023-04-26 Nirsevimabi FIC20230016I1 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461927819P 2014-01-15 2014-01-15
PCT/US2015/011391 WO2015108967A2 (en) 2014-01-15 2015-01-14 Rsv-specific antibodies and functional parts thereof

Publications (1)

Publication Number Publication Date
FIC20230016I1 true FIC20230016I1 (fi) 2023-04-26

Family

ID=53543612

Family Applications (1)

Application Number Title Priority Date Filing Date
FIC20230016C FIC20230016I1 (fi) 2014-01-15 2023-04-26 Nirsevimabi

Country Status (26)

Country Link
US (6) US20160340414A1 (https=)
EP (3) EP3741390A1 (https=)
JP (4) JP6836398B2 (https=)
KR (1) KR102188437B1 (https=)
CN (2) CN116355080A (https=)
AU (4) AU2015206570A1 (https=)
CA (1) CA2933200C (https=)
CY (2) CY1123425T1 (https=)
DK (1) DK3094353T3 (https=)
ES (1) ES2795727T3 (https=)
FI (1) FIC20230016I1 (https=)
FR (1) FR23C1016I1 (https=)
HR (1) HRP20200607T1 (https=)
HU (2) HUE048855T2 (https=)
LT (2) LT3094353T (https=)
LU (1) LUC00305I2 (https=)
MX (1) MX374517B (https=)
NL (1) NL301228I2 (https=)
NO (1) NO2023016I1 (https=)
PL (1) PL3094353T3 (https=)
PT (1) PT3094353T (https=)
RS (1) RS60387B1 (https=)
SI (1) SI3094353T1 (https=)
SM (1) SMT202000282T1 (https=)
TW (1) TWI705974B (https=)
WO (1) WO2015108967A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
ES2795727T3 (es) 2014-01-15 2020-11-24 Medimmune Llc Anticuerpos específicos del vrs y partes funcionales de los mismos
US11479600B2 (en) 2016-10-21 2022-10-25 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
TWI761453B (zh) * 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
KR20200140799A (ko) * 2018-01-31 2020-12-16 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 호흡기 세포융합 바이러스에 대하여 사용하기 위한 핵산 항체 작제물
CN111606993B (zh) * 2019-02-26 2022-06-28 中国科学院上海生命科学研究院 抗呼吸道合胞病毒的全人广谱中和抗体4f1及其应用
US12024553B2 (en) 2019-04-30 2024-07-02 Medimmune Limited Dosage regimens for and compositions including anti-RSV antibodies
CA3229901A1 (en) 2021-09-13 2023-03-16 Medimmune Limited Prevention of respiratory syncytial virus lower respiratory tract infection with nirsevimab
CN119264248A (zh) * 2022-07-22 2025-01-07 北京智仁美博生物科技有限公司 抗呼吸道合胞病毒中和性抗体及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
WO2006050166A2 (en) * 2004-10-29 2006-05-11 Medimmune, Inc. Methods of preventing and treating rsv infections and related conditions
AU2005335714B2 (en) * 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
MX2009003306A (es) 2006-10-02 2009-04-23 Medarex Inc Anticuerpos humanos que se unen a cxcr4 y sus usos.
JP2010534057A (ja) * 2007-03-06 2010-11-04 シムフォゲン・アクティーゼルスカブ 呼吸器合胞体ウイルス感染症を治療するための組換え抗体
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US20110008329A1 (en) * 2007-06-26 2011-01-13 Medlmmune, Llc Methods of Treating RSV Infections And Related Conditions
US8092804B2 (en) * 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
TWI478937B (zh) 2008-01-15 2015-04-01 Abbvie Inc 改良之哺乳動物表現載體及其用途
US9273118B2 (en) * 2009-07-15 2016-03-01 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
JP5762408B2 (ja) * 2009-08-13 2015-08-12 クルセル ホランド ベー ヴェー ヒト呼吸器合胞体ウイルス(rsv)に対する抗体および使用方法
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
EP2486053B1 (en) * 2009-10-06 2017-01-18 Medimmune Limited Rsv-specific binding molecule
US20120263715A1 (en) 2009-10-28 2012-10-18 Medimmune, Llc Topical Methods Of Treating RSV Infections And Related Conditions
BR112012031638B1 (pt) * 2010-07-09 2021-01-12 Janssen Vaccines & Prevention B.V. anticorpo anti-rsv ou fragmento de ligação de antígeno do mesmo, anticorpo multivalente, composição farmacêutica, uso de anticorpo ou fragmento de ligação de antígeno, método de detectar infecção por rsv, e, ácido nucleico isolado
CA2867444C (en) * 2012-03-16 2021-04-13 University Health Network Compositions containing soluble toso protein and uses thereof
US20150158942A1 (en) * 2012-05-22 2015-06-11 Shire Human Genetic Therapies, Inc. Anti-ccl2 antibodies for treatment of scleroderma
CA2900110A1 (en) 2013-02-01 2014-08-07 Medimmune, Llc Respiratory syncytial virus f protein epitopes
ES2795727T3 (es) * 2014-01-15 2020-11-24 Medimmune Llc Anticuerpos específicos del vrs y partes funcionales de los mismos
TWI761453B (zh) 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
BR112019018022A2 (pt) 2017-03-01 2020-06-02 Medimmune Limited Formulações de anticorpos monoclonais

Also Published As

Publication number Publication date
EP3094353A4 (en) 2017-09-06
NO2023016I1 (no) 2023-04-25
CY2023011I1 (el) 2023-11-15
JP2025063143A (ja) 2025-04-15
US11661449B2 (en) 2023-05-30
US12173050B2 (en) 2024-12-24
CN116355080A (zh) 2023-06-30
ES2795727T3 (es) 2020-11-24
MX374517B (es) 2025-03-06
US20220098285A1 (en) 2022-03-31
PT3094353T (pt) 2020-06-08
WO2015108967A3 (en) 2015-09-03
CA2933200A1 (en) 2015-07-23
US20250179153A1 (en) 2025-06-05
FR23C1016I1 (fr) 2023-06-23
AU2015206570A1 (en) 2016-07-14
HK1225992A1 (en) 2017-09-22
US20160340414A1 (en) 2016-11-24
TWI705974B (zh) 2020-10-01
AU2021204339B2 (en) 2024-11-14
LUC00305I2 (https=) 2025-09-22
CY2023011I2 (el) 2023-11-15
EP3094353A2 (en) 2016-11-23
AU2020203831A1 (en) 2020-07-02
CA2933200C (en) 2025-05-06
EP3741390A1 (en) 2020-11-25
CY1123425T1 (el) 2021-12-31
RS60387B1 (sr) 2020-07-31
US20190106482A1 (en) 2019-04-11
EP3094353B1 (en) 2020-04-01
BR112016015044A2 (pt) 2017-09-19
SMT202000282T1 (it) 2020-07-08
JP2017504321A (ja) 2017-02-09
JP2020103293A (ja) 2020-07-09
HRP20200607T1 (hr) 2020-07-10
ES2795727T9 (en) 2026-01-21
PL3094353T3 (pl) 2020-09-07
BR112016015044A8 (pt) 2023-04-11
HUE048855T2 (hu) 2020-08-28
AU2025201056A1 (en) 2025-03-06
JP2023052693A (ja) 2023-04-11
NL301228I1 (https=) 2023-05-03
LT3094353T (lt) 2020-08-10
HUS2300019I1 (hu) 2023-05-28
EP4353316A2 (en) 2024-04-17
WO2015108967A2 (en) 2015-07-23
AU2021204339A1 (en) 2021-07-22
WO2015108967A8 (en) 2015-10-01
MX2016008639A (es) 2017-02-15
TW201612191A (en) 2016-04-01
RU2016133247A3 (https=) 2019-01-16
SI3094353T1 (sl) 2020-07-31
DK3094353T3 (da) 2020-06-02
EP4353316A3 (en) 2024-08-21
JP6836398B2 (ja) 2021-03-03
LTC3094353I2 (https=) 2025-07-10
US11186628B2 (en) 2021-11-30
NL301228I2 (nl) 2023-09-13
CN105916520A (zh) 2016-08-31
RU2016133247A (ru) 2018-02-20
KR102188437B1 (ko) 2020-12-08
LTPA2023514I1 (https=) 2023-05-25
KR20160104018A (ko) 2016-09-02
US20230365660A1 (en) 2023-11-16
US10689437B2 (en) 2020-06-23
US20200331989A1 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
DK3183051T3 (da) Væske-til-luftmembranenergivekslere
DK3134402T3 (da) 4-amino-imidazoquinolinforbindelser
DK3006072T3 (da) Karadgang
DK3222714T3 (da) Phytasemutanter
DK3119396T3 (da) Muscarinreceptoragonister
EP3230438C0 (en) N-GLYCOSYLATION
NL301228I2 (nl) nirsevimab
EP4011484C0 (en) CARBONIC ANHYDRASE OF THERMOVIBRIO AMMONIFICANS
DK4242916T3 (da) Forstøver
DE112015001664A5 (de) Betätigungsaktuator
DK3154703T3 (da) Fuldkappe-snekkecentrifuge
DE112015005041A5 (de) Gargerätevorrichtung
DK3110439T3 (da) Pcsk9-vacciner
DE102014000623A8 (de) Halbhohlnietelement
DK3009858T3 (da) Skyradar
DE202014005655U8 (de) llluminationsvorrichtung
DE112015001633A5 (de) Betätigungsaktuator
DK3447493T3 (da) Proteinrettede ortologer
ES1133830Y (es) Columbario
DE112015005055A5 (de) Gargerätevorrichtung
DK3091875T3 (da) Vipbar taburet
ES1114205Y (es) Heliostato
FI10894U1 (fi) Putkieristyskouru
ES1137381Y (es) Trompo
ES1136185Y (es) Huevera